|
End-of-day quote
New Zealand S.E.
17/09/2026
|
5-day change | 1st Jan Change | ||
| 4.290 NZD | -0.23% |
|
-2.28% | +26.92% |
| 09/09 | Aft Pharmaceuticals Limited Partners with Mark Cuban Cost Plus Drug Company to Bring Combogesic to the U.S | CI |
| 31/07 | AFT Pharmaceuticals Limited - Shareholder/Analyst Call |
| Market Cap | 450M 258M 225M 213M 193M 361M 24.7B 363M 2.53B 979M 12.55B 969M 947M 40.19B | P/E 2027 * |
22.8x | P/E 2028 * | 18.1x |
|---|---|---|---|---|---|
| Enterprise Value | 480M 275M 240M 227M 206M 385M 26.34B 387M 2.7B 1.04B 13.39B 1.03B 1.01B 42.85B | EV / Sales 2027 * |
1.58x | EV / Sales 2028 * | 1.37x |
| Free-Float |
22.37% | Yield 2027 * |
0.76% | Yield 2028 * | 0.97% |
| Markets | Quality | ||
|---|---|---|---|
New Zealand S.E.
| AFT | End-of-day quote | |
Australian S.E.
| AFP | Delayed |
Last Transcript: AFT Pharmaceuticals Limited
| 20/01/24 | Rentevrees zet Bel20 onder druk | |
| 19/01/24 | KBC uitblinker op groene beurs | |
| 19/01/24 | Brusselse beurs opent flink hoger | |
| 19/01/24 | Brussel start handelsdag vermoedelijk in het groen | |
| 19/01/24 | Hyloris gaat samenwerken met AFT Pharmaceuticals |
| 1 day | -0.23% | ||
| 1 week | -2.28% | ||
| Current month | -3.38% | ||
| 1 month | -0.23% | ||
| 3 months | +11.43% | ||
| 6 months | +22.57% | ||
| Current year | +26.92% |
| 1 week | 4.29 |  | 4.39 |
| 1 month | 4.23 | | 4.54 |
| Current year | 3.35 | | 4.85 |
| 1 year | 2.57 | | 4.85 |
| 3 years | 2.37 | | 4.85 |
| 5 years | 2.37 | | 5 |
| 10 years | 1.7 | | 5.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marree Atkinson
HRO | Human Resources Officer | - | 04/09/2012 |
Hartley Atkinson
CEO | Chief Executive Officer | - | 04/09/1997 |
Stuart Houliston
DFI | Director of Finance/CFO | - | 15/06/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
David Flacks
CHM | Chairman | - | 22/06/2015 |
Hartley Atkinson
BRD | Director/Board Member | - | 04/09/1997 |
Marree Atkinson
BRD | Director/Board Member | - | 04/09/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/7/25 | Buy | Founder | 200,000 | 0.1907% | ||
| 26/6/25 | Free | Founder | 17,755 | 0.0169% | ||
| 2/12/24 | Buy | Founder | 45 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.23% | -2.28% | +65.00% | +22.92% | 258M | |
| -0.35% | +2.82% | +50.36% | +100.80% | 1,027B | |
| -0.57% | +1.08% | +54.14% | +65.23% | 651B | |
| +0.06% | +2.65% | +18.89% | +71.45% | 467B | |
| -1.05% | +3.95% | +36.83% | +38.71% | 350B | |
| -0.53% | +2.98% | +19.32% | +25.39% | 268B | |
| +0.14% | +6.30% | +10.65% | +16.01% | 257B | |
| +0.64% | +1.03% | +38.21% | +44.87% | 205B | |
| +0.55% | +1.43% | -28.56% | -56.89% | 190B | |
| -0.24% | +4.46% | +32.14% | +98.54% | 187B | |
| Average | -0.13% | +2.17% | +29.70% | +42.70% | 360.24B | |
| Weighted average by Cap. | -0.25% | +2.62% | +34.72% | +61.26% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 304M 174M 152M 144M 130M 244M 16.68B 245M 1.71B 661M 8.48B 654M 640M 27.14B | 345M 198M 172M 163M 148M 277M 18.96B 278M 1.94B 751M 9.63B 744M 727M 30.84B |
| Net income | 19.7M 11.29M 9.83M 9.31M 8.46M 15.8M 1.08B 15.88M 111M 42.87M 550M 42.42M 41.47M 1.76B | 24.81M 14.23M 12.39M 11.73M 10.65M 19.9M 1.36B 20M 140M 54.01M 692M 53.44M 52.25M 2.22B |
| Net Debt | 29.84M 17.1M 14.9M 14.1M 12.81M 23.93M 1.64B 24.05M 168M 64.94M 833M 64.26M 62.83M 2.67B | 24.6M 14.1M 12.28M 11.62M 10.56M 19.73M 1.35B 19.83M 138M 53.54M 686M 52.97M 51.79M 2.2B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/09/26 | NZD 4.300 | +0.23% | 114,414 |
| 17/09/26 | NZD 4.290 | -0.23% | 63,940 |
| 16/09/26 | NZD 4.300 | -0.69% | 54,735 |
| 15/09/26 | NZD 4.330 | +0.23% | 32,780 |
| 14/09/26 | NZD 4.320 | 0.00% | 9,746 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AFT Stock
Select your edition
All financial news and data tailored to specific country editions
